JP2019502694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502694A5 JP2019502694A5 JP2018531487A JP2018531487A JP2019502694A5 JP 2019502694 A5 JP2019502694 A5 JP 2019502694A5 JP 2018531487 A JP2018531487 A JP 2018531487A JP 2018531487 A JP2018531487 A JP 2018531487A JP 2019502694 A5 JP2019502694 A5 JP 2019502694A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- amino acid
- acid sequence
- polypeptide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 372
- 229920001184 polypeptide Polymers 0.000 claims description 365
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 365
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 310
- 235000001014 amino acid Nutrition 0.000 claims description 185
- 229940024606 amino acid Drugs 0.000 claims description 176
- 150000001413 amino acids Chemical class 0.000 claims description 146
- 239000000427 antigen Substances 0.000 claims description 116
- 102000036639 antigens Human genes 0.000 claims description 116
- 108091007433 antigens Proteins 0.000 claims description 116
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 65
- 238000005734 heterodimerization reaction Methods 0.000 claims description 56
- 239000012634 fragment Substances 0.000 claims description 37
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 31
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 24
- 239000004472 Lysine Substances 0.000 claims description 24
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 14
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 14
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 14
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 14
- 230000004988 N-glycosylation Effects 0.000 claims description 14
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 14
- 239000004473 Threonine Substances 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 14
- 229960001230 asparagine Drugs 0.000 claims description 14
- 235000009582 asparagine Nutrition 0.000 claims description 14
- 239000000539 dimer Substances 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 11
- 229940094342 human immunoglobulin m Drugs 0.000 claims description 11
- 102000018358 immunoglobulin Human genes 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- 235000018417 cysteine Nutrition 0.000 claims description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 3
- 239000000833 heterodimer Substances 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021092180A JP2021121642A (ja) | 2015-12-18 | 2021-06-01 | 二特異性抗体基幹 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269664P | 2015-12-18 | 2015-12-18 | |
| US62/269,664 | 2015-12-18 | ||
| PCT/US2016/066865 WO2017106462A1 (en) | 2015-12-18 | 2016-12-15 | Bispecific antibody platform |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021092180A Division JP2021121642A (ja) | 2015-12-18 | 2021-06-01 | 二特異性抗体基幹 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502694A JP2019502694A (ja) | 2019-01-31 |
| JP2019502694A5 true JP2019502694A5 (enExample) | 2020-01-16 |
| JP7138046B2 JP7138046B2 (ja) | 2022-09-15 |
Family
ID=57681809
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531487A Active JP7138046B2 (ja) | 2015-12-18 | 2016-12-15 | 二特異性抗体基幹 |
| JP2021092180A Pending JP2021121642A (ja) | 2015-12-18 | 2021-06-01 | 二特異性抗体基幹 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021092180A Pending JP2021121642A (ja) | 2015-12-18 | 2021-06-01 | 二特異性抗体基幹 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11447575B2 (enExample) |
| EP (1) | EP3389710A1 (enExample) |
| JP (2) | JP7138046B2 (enExample) |
| KR (1) | KR20180100136A (enExample) |
| CN (1) | CN108601830B (enExample) |
| AU (1) | AU2016370821A1 (enExample) |
| CA (1) | CA3008840A1 (enExample) |
| MA (1) | MA44054A (enExample) |
| WO (1) | WO2017106462A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7366742B2 (ja) * | 2016-08-26 | 2023-10-23 | サノフイ | 選択的な軽鎖対形成を容易にする多重特異性抗体 |
| EP3661555B1 (en) | 2017-08-01 | 2025-04-16 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| CN110028588A (zh) * | 2018-01-11 | 2019-07-19 | 上海细胞治疗研究院 | 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用 |
| KR20210111242A (ko) | 2018-10-29 | 2021-09-10 | 바이오젠 엠에이 인코포레이티드 | 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체 |
| CA3120800A1 (en) | 2018-12-17 | 2020-06-25 | Revitope Limited | Twin immune cell engager |
| US12463463B2 (en) | 2019-01-28 | 2025-11-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| US20220227827A1 (en) * | 2019-03-25 | 2022-07-21 | Dingfu Biotarget Co., Ltd. | Proteinaceous heterodimer and use thereof |
| TWI890689B (zh) * | 2019-08-15 | 2025-07-21 | 美商再生元醫藥公司 | 用於細胞靶向之多特異性抗原結合分子及其用途 |
| BR112022003282A2 (pt) * | 2019-08-23 | 2022-05-24 | Igm Biosciences Inc | Glicovariantes de igm |
| MX2022003507A (es) * | 2019-09-25 | 2022-04-25 | Univ Stuttgart | Modulos de union que comprenden dominios ehd2 modificados. |
| AU2021205561A1 (en) * | 2020-01-09 | 2022-08-11 | Jiangsu Hengrui Medicine Co., Ltd. | New polypeptide complex |
| CN113307879A (zh) * | 2020-02-27 | 2021-08-27 | 启愈生物技术(上海)有限公司 | 一种taa/ctla-4/il15三功能融合蛋白及其应用 |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| MX2023005197A (es) * | 2020-11-06 | 2023-05-16 | Amgen Inc | Dominio de union a antigeno con tasa de recorte reducida. |
| MX2023013307A (es) * | 2021-05-14 | 2023-12-04 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Molecula de union a antigeno. |
| US20250163144A1 (en) | 2021-07-27 | 2025-05-22 | Novab, Inc. | Engineered vlrb antibodies with immune effector functions |
| WO2024073482A1 (en) * | 2022-09-28 | 2024-04-04 | Dren Bio, Inc. | Multispecific antibodies and methods of use thereof |
| WO2025042806A2 (en) | 2023-08-21 | 2025-02-27 | Modernatx, Inc. | C-met binding antibodies, nucleic acids encoding same, and methods of use |
| WO2026044055A1 (en) | 2024-08-23 | 2026-02-26 | Modernatx, Inc. | Muc16 binding molecules, nucleic acids encoding same, and methods of use |
| CN121148519B (zh) * | 2025-11-18 | 2026-02-13 | 西北农林科技大学 | 基于计算模拟辅助的双特异性抗体分子设计与优化方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162359A1 (en) * | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| CA2824824A1 (en) * | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
| US9738707B2 (en) * | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
| WO2013156054A1 (en) * | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
| KR20150013188A (ko) * | 2012-05-24 | 2015-02-04 | 에프. 호프만-라 로슈 아게 | 다중특이적 항체 |
| CN105636986B (zh) | 2013-10-18 | 2020-05-12 | 瑞泽恩制药公司 | 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物 |
| ES2935274T3 (es) * | 2014-12-05 | 2023-03-03 | Merck Patent Gmbh | Anticuerpo con intercambio de dominios |
| WO2017011342A1 (en) | 2015-07-10 | 2017-01-19 | Abbvie Inc. | Igm-or-ige-modified binding proteins and uses thereof |
| JP7366742B2 (ja) * | 2016-08-26 | 2023-10-23 | サノフイ | 選択的な軽鎖対形成を容易にする多重特異性抗体 |
| CA3120800A1 (en) * | 2018-12-17 | 2020-06-25 | Revitope Limited | Twin immune cell engager |
-
2016
- 2016-12-15 MA MA044054A patent/MA44054A/fr unknown
- 2016-12-15 US US16/061,903 patent/US11447575B2/en active Active
- 2016-12-15 CN CN201680081272.6A patent/CN108601830B/zh active Active
- 2016-12-15 KR KR1020187020661A patent/KR20180100136A/ko not_active Abandoned
- 2016-12-15 EP EP16820131.7A patent/EP3389710A1/en active Pending
- 2016-12-15 AU AU2016370821A patent/AU2016370821A1/en not_active Abandoned
- 2016-12-15 JP JP2018531487A patent/JP7138046B2/ja active Active
- 2016-12-15 WO PCT/US2016/066865 patent/WO2017106462A1/en not_active Ceased
- 2016-12-15 CA CA3008840A patent/CA3008840A1/en active Pending
-
2021
- 2021-06-01 JP JP2021092180A patent/JP2021121642A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502694A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| JP2016527314A5 (enExample) | ||
| JP6606505B2 (ja) | 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体 | |
| JP2020508655A5 (enExample) | ||
| HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
| JP2017504577A5 (enExample) | ||
| US20170210818A1 (en) | Constant region antibody fusion proteins and compositions thereof | |
| JP2021503455A5 (enExample) | ||
| JP2020524510A5 (enExample) | ||
| JP2017522891A5 (enExample) | ||
| US20220340677A1 (en) | Split intein and preparation method for recombinant polypeptide using the same | |
| JP2016525551A5 (enExample) | ||
| JP2019524693A5 (enExample) | ||
| RU2016108703A (ru) | Антитело, специфически связывающееся с glp-1r, и его слитый с glp-1 белок | |
| JP2019512207A5 (enExample) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| JP2017536128A (ja) | ドメイン交換抗体 | |
| JP2010539921A5 (enExample) | ||
| WO2018119118A4 (en) | Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| CA2970800A1 (en) | Monomeric fc domains | |
| JP2014158485A5 (enExample) | ||
| JP2014519322A5 (enExample) | ||
| HRP20201191T1 (hr) | Mutirani multispecifični fab fragmenti antitijela |